申请人:RICHTER GEDEON VEGYESZETI GYAR RT.
公开号:US20030199552A1
公开(公告)日:2003-10-23
New Formula (I) compounds are disclosed having NR2B selective NMDA receptor antagonist activity
1
wherein
one of the neighboring R
1
, R
2
, R
3
and R
4
groups is OH or NH2 and the others are each hydrogen , or
two of the neighboring R
1
, R
2
R
3
and R
4
groups in given case together with one or more identical or different additional hetero atom and —CH═ and/or —CH
2
— groups forms a 5-6 membered homo- or heterocyclic ring, preferably pyrrole, pyrazole, imidazole, oxazole, oxo-oxazolidine, or 3-oxo-1,4-oxazine ring, and the other two of R
1
, R
2
, R
3
and R
4
groups are is hydrogen atoms,
R
5
and R
6
together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by hydroxy group, and/or in given case phenyl or phenoxy, phenyl-(C
1
-C
4
alkyl), phenyl-(C
1
-C
4
alkoxy), phenoxy-(C
1
-C
4
alkyl), anilino, phenyl-(C
1
-C
4
alkylamino), [phenyl-(C
1
-C
4
alkyl)]-amino, benzoyl, hydroxy-diphenylmethyl, C
1
-C
4
alkoxycarbonyl-phenoxymethyl or benzhydrylidene group, optionally substituted on the aromatic ring by one or more halogen atom, cyano or hydroxy group, C
1
-C
4
alkyl or C
1
-C
4
alkoxy group,
X is independently oxygen, —NH— or a CH2 group,
Y is independently a nitrogen atom or a —CH— group,
and the salts thereof formed with acids and bases.
揭示了具有NR2B选择性NMDA受体拮抗活性的新配方(I)化合物,其中相邻的R1、R2、R3和R4基团中的一个是OH或NH2,其他基团均为氢,或者在某些情况下,相邻的R1、R2、R3和R4基团中的两个与一个或多个相同或不同的额外杂原子和—CH和/或—CH2—基团一起形成5-6元素的同源或异源环,优选为吡咯、吡唑、咪唑、噁唑、噁唑烷酮或3-氧代-1,4-噁唑环,并且R1、R2、R3和R4中的另外两个基团是氢原子,R5和R6与它们之间的氮原子一起形成饱和或不饱和的、4-6元素的杂环,该环被羟基取代,或者在某些情况下为苯基或苯氧基、苯基-(C1-C4烷基)、苯基-(C1-C4氧基)、苯氧基-(C1-C4烷基)、苯胺基、苯基-(C1-C4烷基氨基)、[苯基-(C1-C4烷基)]-氨基、苯甲酰基、羟基-二苯甲基、C1-C4烷氧羰基-苯氧基甲基或苯甲亚乙基基团取代的芳环,该芳环上可以进一步取代一个或多个卤素原子、氰基或羟基、C1-C4烷基或C1-C4氧基基团,X独立地为氧、—NH—或CH2基团,Y独立地为氮原子或—CH—基团,以及与酸和碱形成的盐。